Pembrolizumab monotherapy in the first-line treatment of EGFR/ALK wildtype, PD-L1 tumor proportion score (TPS) 1–49%, advanced non-small cell lung cancer (NSCLC): con: “It takes two to tango”
@article{PCM5885, author = {Claire Griffiths and Smitha Menon}, title = {Pembrolizumab monotherapy in the first-line treatment of EGFR/ALK wildtype, PD-L1 tumor proportion score (TPS) 1–49%, advanced non-small cell lung cancer (NSCLC): con: “It takes two to tango”}, journal = {Precision Cancer Medicine}, volume = {3}, number = {0}, year = {2020}, keywords = {}, abstract = {}, issn = {2617-2216}, url = {https://pcm.amegroups.org/article/view/5885} }